- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diagnosis of Intestinal Parasites
- Drug Monitoring, Antidepressants, With Confirmation, Urine and Serum
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Lyme Disease Testing
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- No FAQs found
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Porphyria Testing
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- SARS-CoV-2 Serology (COVID-19) Antibody (IgG), Immunoassay
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Triple ScreenTest code(s) 7292, 16334 (NY)
Question 1. My patient had a negative Triple Screen. What should I do next?
Prenatal screening provides information about a fetus’s chance of having trisomy 21 (Down syndrome), trisomy 18, or an open neural tube defect (ONTD). Prenatal diagnosis will tell whether or not the fetus has any of these disorders. A negative screen means it is unlikely the fetus has Down syndrome, trisomy 18, or an open neural tube defect. But a negative screen does not guarantee the birth of a healthy baby. The screening test only screens for Down syndrome, trisomy 18, and ONTDs; it is not a diagnostic test.
The demographic information provided at the time of testing is used in calculating the patient’s risk of having a fetus with Down syndrome, trisomy 18, or ONTD. Please check the demographic information to ensure accuracy of calculated results.
Question 2. My patient’s result was screen positive for Down syndrome. What should I do next?
A positive Down syndrome screen result means there is an increased risk for the fetus to be affected with Down syndrome or other chromosome abnormality. Ultrasound confirmation of gestational age is recommended. If there is a greater than 10 day difference between the expected date of delivery (EDD) used in the screen and the ultrasound EDD, please contact the maternal serum screening laboratory to recalculate results. If the gestational age has been confirmed, the patient should be counseled regarding diagnostic testing options (eg, chromosome analysis of an amniocentesis sample) and/or prenatal cell-free DNA (cfDNA--QNatal AdvancedTM; test code 92777[X]). Guidelines recommend against repeating this Triple Screen test when it is screen positive for Down syndrome.1
A positive trisomy 18 result means there is an increased risk for the fetus to be affected with trisomy 18 or other chromosome abnormality. The patient should be counseled regarding a detailed fetal anatomic scan and diagnostic testing options (eg, chromosome analysis of an amniocentesis sample) and/or prenatal cell-free DNA (cfDNA—Qnatal AdvancedTM; test code 92777[X]).
Guidelines do not recommend recalculating results based on a revised EDD/gestational age nor do they recommend repeating a trisomy 18 positive screening test. As intrauterine growth restriction is a prominent feature of trisomy 18, recalculating may change a true-positive result to a false-negative result. Furthermore, it’s very unlikely that the typical marker pattern (low AFP, uE3, and hCG) seen in a trisomy 18 positive screen will normalize after recalculation.
Question 4. My patient’s result was screenpositive for ONTD. What should I do next?
A positive ONTD screen result means there is an increased risk for the fetus to be affected with an open neural tube defect or other congenital abnormality. If the patient’s AFP is less than 3.5 multiples of the median (MoM), if ultrasound dating confirms the gestational age and a singleton pregnancy, and if the gestational age is less than 18 weeks, testing a newly collected sample can be considered. If this second sample confirms an elevated AFP MoM or if a second AFP test is not performed, genetic counseling, ultrasound examination, and possible amniocentesis would be appropriate.
Note that underestimation of gestational age is one of the most frequent causes of an elevated MoM.
Question 5. The report indicates a different gestational age than what I determined. How is the gestational age calculated?
The gestational age is reported in decimal weeks; for example, 15 weeks 4 days is reported as 15.6 weeks. This is derived from the EDD and the collection date provided; it is an exact calculation by calendar days. Gestational wheels may be inaccurate by several days or more.
Question 6. When is it appropriate to change the gestational age or estimated date of delivery (EDD) on a maternal serum screen result report?
It is appropriate to change the gestational age or EDD when the data used for screening are substantially above or below that determined by ultrasound. In case of a positive screen for trisomy 18, however, guidelines recommend against changing the gestational age or EDD (see Question 3).
The earliest EDD calculated by ultrasound should be used for dating purposes.2 An ultrasound derived EDD is most accurate when determined in the first trimester. Accuracy decreases with advancing gestational age. For example, accuracy of an ultrasound EDD is ±7 days in the first trimester and ±10 days in the second trimester.
If a first trimester ultrasound EDD is available and the gestational age used for screening is within the EDD ±7 days, the gestational age should not be changed for screening purposes. Similarly, if second trimester (but not first trimester) EDD is available and the gestational age used for screening is within the EDD ±10 day range, the gestational age should not be changed for screening purposes. If the gestational age used for screening is outside the ultrasound EDD range, it may be appropriate to change the gestational age used for screening.
If you want to change the EDD/gestational age used for a specific patient’s screening test, please contact your local Quest Diagnostics laboratory or call Quest Genomics Client Services at 866.GENE.INFO. If the revised gestational age is between 15.0 to 22.9 weeks gestation, we can calculate and report new risks. If the revised gestational age is ≥14.0 weeks and <15.0 weeks, we can calculate and report new Down syndrome and trisomy 18 risks, but not ONTD risks (see Question 7). If the revised gestational age is <14.0 weeks, consider submitting a second specimen for screening, collected when the patient is between 15.0 to 22.9 weeks gestation (preferably 16 to 18 weeks). If the revised gestational age is >22.9 weeks gestation, we cannot calculate new risks, and a more accurate risk assessment cannot be provided.
Question 7. Why is there no ONTD risk reported for samples collected during 14.0 – 14.9 weeks gestation?
The NTD detection rate is significantly lower at 14.0 to 14.9 weeks gestation than at 15.0 to 22.9 weeks gestation. Therefore, samples collected during the 14th week of gestation with an AFP value below 2.5 MoM (single gestation, nondiabetic) will be reported as screen negative without a patient-specific risk. For optimal NTD screening, collect samples when the patient is at 16 to 18 weeks gestation.
Question 8. My patient has a family history of NTD, Down syndrome, or trisomy 18. What impact does this have on these results?
Please call Quest Genomics Client Services at 866.GENE.INFO to discuss this case with a genetic counselor. Documentation of the abnormality in the family may enable a more specific risk assessment or indicate whether additional studies should be performed.
Question 9. My patient had a normal maternal serum screen, but her risk for Down syndrome was higher than her age-related risk. Why was her result screen negative?
A cutoff of 1 in 270, the risk of a 35-year old, is used to determine if a pregnancy is screen negative or screen positive for Down syndrome. This cutoff is used regardless of the patient’s age, since it’s the historical cutoff for offering diagnostic testing (amniocentesis).
When counseling a pregnant patient, it may be helpful to compare her age-related risk (ie, pre-test risk) with her screen-derived risk (post-test risk) and the general population risk (1 in 600-800 live births). This allows the patient and her partner to better understand her risk of carrying a Down-syndrome affected fetus and to weigh it against the risks and consequences of amniocentesis or cfDNA.
There is no consensus in the literature as to what constitutes a low unconjugated estriol (uE3) level. Therefore, no results will be flagged as low on the report. However, most centers consider the uE3 low if the MoM is <0.25. Some centers even consider anything <0.30 MoM as low.
A low uE3 MoM has been associated with fetal Smith-Lemli-Opitz syndrome (SLOS), steroid sulfatase deficiency (STSD), and some disorders of esterol biosynthesis. In about 60% of SLOS cases, the maternal serum uE3 is <0.3 MoM, while in STSD, the uE3 is often ≤0.1 MoM.
Diagnostic tests can be done using amniotic fluid samples. An SLOS test is performed at the Kennedy-Kreiger Institute (http://www.kennedykrieger.org/patient-care/patient-care-laboratories/genetics-laboratories/clinical-services/biochemical-testing). Quest Diagnostics offers a FISH test for STSD (FISH, X-Linked Ichthyosis Steroid Sulfatase Deficiency, test code 14607[X]).
Question 11. Do low or high concentrations of specific analytes suggest problems other than a chromosome defect or ONTD?
Low or high analyte levels have been associated with the following pregnancy complications: low birth weight, intrauterine growth retardation, preterm labor, preeclampsia, and fetal demise.
Low uE3 values have been associated with Smith-Lemli-Opitz syndrome and steroid sulfatase deficiency. See Question 10 for more information.
Question 12. What is a Down syndrome pseudo-risk in a twin gestation? Why don't you give twin-specific risks?
Prenatal screening in twin pregnancies is complex. The serum markers can be measured in a patient with a twin gestation and then divided by corresponding medians for unaffected singleton pregnancies to calculate multiple of medians (MoMs). These MoMs are then adjusted for twins in order to provide a pseudo-risk for Down syndrome.
This calculation accounts for the presence of two fetuses, but does not take into account the chorionicity of the pregnancy. The result is a pregnancy-specific pseudo-risk, rather than a fetus-specific risk.
Question 13. In a twin gestation, why are there no numerical risk assessments reported for open neural tube defects (ONTD) or trisomy 18?
Prenatal screening in twin pregnancies is complex. The AFP MoM is adjusted based on the number of fetuses to provide either an ONTD screen negative or screen positive result. An ONTD numerical risk estimate cannot becalculated due to insufficient data from affected twin pregnancies.
A trisomy 18 risk assessment is not calculated in a twin gestation due to insufficient screening marker data from affected twin pregnancies.
Question 14. When is it appropriate to offer the Triple Screen test?
While the Triple Screen test screens for Down syndrome, trisomy 18, and ONTDs, other maternal screening tests provide a higher detection rate at the same, or lower, false-positive rate. For example, if the patient presents in the first trimester, an Integrated Screen has a Down syndrome detection rate of 92% (3% FPR). Alternatively, if the patient presents in the second trimester, a Penta Screen has a Down syndrome detection rate of 83%
(5% FPR). These compare to the Triple Screen Down syndrome detection rate of 69% (5% FPR).
1. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109:217-227.
2. American College of Obstetricians and Gynecology. Committee Opinion No 611: Method for estimating due date. Obstet Gynecol. 2014;124:863-866.